British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals

Lancet

Volumn 349, Issue 9058, 1997, Pages 1086-1092

  Gazzard, Brian G ^a   Moyle, G J ^b   Weber, J ^b   Johnson, M ^b   Bingham, J S ^b   Brettle, R ^b   Churchill, D ^b   Fisher, M ^b   Griffin, G ^b   Jefferies, D ^b   King, E ^b   Gormer, R ^b   Lee, C ^b   Pozniak, A ^b   Smith, J R ^b   Tudor Williams, G ^b   Williams, I ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT PLANNING; VIRUS RESISTANCE;

EID: 0030935802     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)12073-0     Document Type: Note

References (40)

1. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine of zalcitabine in HIV-infected patients with the acquired immune deficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-106.
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90.
3. DELTA co-ordinating committee. DELTA: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine or zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283.
4. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased disease progression of HIV in patients treated with saquinavir plus HIVID. XI International Conference on AIDS (Vancouver, July, 1996); LB.B.6033.
5. Katlama C on behalf of the CAESAR co-ordinating committee. Clinical and survival benefit of 3TC in combination with zidovudine-containing regimens in HIV-1 infection: interim results of the CAESAR study. 3rd International Congress on Drug Therapy in HIV Infection (Birmingham, UK, November, 1996): abstr SS2.1.
6. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996; 276: 146-54.
7. Anon. Didanosine and ACTG 116A. Lancet 1993; 341: 109.
8. Katzenstein DA, Hammer SM, Hughes MD, et al.The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-98.
9. Schooley RT, Ramirez-Ronda C, Lange JMA, et al. Virologic and immunological benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine alone. J Infect Dis 1996; 173: 1354-66.
10. Richman DD, Meng TC, Spector SA, Fischl MA, Resnick L, Lai S. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7: 135-38.
11. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333: 1662-69.
12. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral naive patients: a randomised controlled comparison with zidovudine monotherapy. JAMA 1996; 276: 118-25.
13. Vella S. Clinical experience with saquinavir. AIDS 1995; 9 (suppl 2): S21-S25.
14. Kavlick MF, Shirasaka T, Kojima E, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′, 3′-dideoxy-3′thiacytidine. Antiviral Res 1995; 28: 133-46.
15. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-87.
16. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32.
17. Hughes MD, De Gruttola, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovir 1995; 10 (suppl 2): S1-S8.
18. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma. Science 1996; 272: 1167-69.
19. O'Brien WA, Hartigan P, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-43.
20. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. N at Med 1996; 2: 625-29.
21. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterisation of long-term survivors of human immunodeficiency type 1 infection. N Engl J Med 1995; 332: 201-08.
22. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-16.
23. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996; 52: 168-85.
24. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124: 654-63.
25. Liuzzi G, Chiriani A, Clementi M, et al. Analysis of HIV-1 load in blood, semen, and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996; 10: F51-F56.
26. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-99.
27. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, Ritonavir. J Infect Dis 1996; 173: 321-29.
28. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-26.
29. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-94.
30. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-89.
31. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
32. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124: 984-94.
33. Portegies P. HIV-1, the brain and combination therapy. Lancet 1995; 346: 1244-45.
34. D'Aquilla RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996; 124: 1019-30.
35. Moyle G. Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996; 5: 155-67.
36. Shapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4T cell counts in HIV infected patients. Ann Intern Med 1996; 124: 1039-50.
37. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701-12.
38. Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71.
39. Tudor-Williams G, Gibb D. HIV infection in children. In: Adler MW, ed. ABC of AIDS, 4th edn. London: BMJ Publishing Group (in press).
40. Sharland M, Tudor-Williams G, Novelli V, et al. Paediatric HIV infection. Arch Dis Child (in press).